The Board of Directors is currently comprised of the CEO and three outside members with expertise in the pharmaceutical and biotechnology industry, IP establishment and protection, and business development.
Glenn Walthall, M.B.A.
Chairman of the Board
Glenn Walthall serves as Gaston Capital's Chief Investment Officer. His career spans twenty-five years as a financial industry consultant (Broadway and Seymour), retail bank executive (First Union Securities and Bank of America), and investment banker. Prior to joining Gaston Capital, Mr. Walthall co-founded Ware River Advisors, LLC, an investment banking firm where he was responsible for arranging growth equity and debt capital and providing M&A advisory services to lower middle market companies across the United States. His industry experience covers areas including financial services, business services, light industrial and manufacturing, information technology and healthcare. Mr. Walthall holds a BA in Business Management and a Masters in Business Administration from Virginia Tech.
David Robb, M.A.
David Robb serves as President and COO Gaston Capital Partners, LLC. He began his career in financial services, first as an economist and asset allocation specialist for First Chicago Investment Advisors, a large pension fund management firm, before becoming an interest rate futures broker and trader for The Chicago Corporation. From Chicago, he returned to his hometown of Charlotte to begin a series of entrepreneurial ventures, first in graphic arts and later in a series of internet technology companies in New York, Charlotte, and Seattle. He served on as a director of the Application Developers Alliance and sits on numerous corporate boards in the Gaston Capital Portfolio. He has extensive experience in real estate development, manufacturing and medical technology.
In addition to his corporate board participation, David has served on many nonprofits, primarily focused on environmental causes and animal welfare. He is the chair of Humane Society of the United States North Carolina State Council, a director of Humane Society Legislative Fund and is a long time director of the North Carolina Zoological Society. He holds a B.A. in Business Management from NC State University and an M.A. in economics from Duke University.
Hooshmand Sheshbaradaran, Ph.D.
Hooshmand Sheshbaradaran, Ph.D., is a current member of the Board of Directors after serving as Niiki Pharma's Chief Executive Officer. He has spent his career in development and marketing of several cancer drugs, including Camptosar®, Ellence®, Emcyt®, Sutent®, and Vidaza®. Prior to founding Niiki Pharma, Dr. Sheshbaradaran was the head of the US subsidiary of Zeneus Pharma Ltd., a venture-backed oncology company acquired by Cephalon, Inc., for $360 million in 2007. Previously he held senior executive positions including Global Director of Oncology Business Development at Roche and Global Director of Oncology, New Products Marketing, at Pharmacia/Pfizer. Dr. Sheshbaradaran earned his Ph.D. from the Karolinksa Institute and held post-doctoral research positions at Northwestern University.
E. Russell McAllister, M.Acc., M.B.A., C.M.B.A.
Mr. McAllister brings more than 15 years of business development, corporate finance, leadership and strategic advisory experience to the management team at Intezyne. Previously, Mr. McAllister served as the Vice President of Finance for Qu Biologics, a Vancouver, Canada-based clinical-stage immunotherapy company focused on the development of a novel immunomodulator platform technology with applications in both oncology and inflammatory disease, and, prior to that, as the Chief Financial Officer for Lakewood-Amedex, a clinical-stage infectious disease company focused on the development of novel antimicrobial and nRNA platform technologies. Earlier in his career, Mr. McAllister worked in both New York and San Francisco as a Managing Director of Healthcare Investment Banking at H.C. Wainwright (formerly Rodman & Renshaw) and various other healthcare-focused banks, where he engineered the private and public offerings and/or turnarounds of numerous micro- and small-cap biopharmaceutical companies, successfully raising more than $1 billion in capital for his clients in the process. Prior to moving into investment banking, Mr. McAllister worked as a Senior Biopharmaceuticals Equity Research Analyst at Thomas Weisel Partners and Merriman Curhan Ford & Co., where he received 5-star ratings from StarMine. Mr. McAllister began his career as a Senior Accountant in Forensic Services at PriceWaterhouseCoopers. Mr. McAllister holds Masters degrees in both Accounting and Business (Finance) from Northeastern University and dual Bachelor of Arts degrees in Economics and Asian Studies from Rice University. Mr. McAllister was also a fellowship doctoral candidate in Behavioral Finance at the University of Illinois.